Publications
A2AR Antagonists: Next generation checkpoint blockade for cancer immunotherapy
By Robert D. Leone, Ying-Chun Lo, Jonathan D. Powell
Computational and Structural Biotechnology Journal 13 (2015) 265–272
Targeting adenosine for cancer immunotherapy
By Robert D. Leone and Leisha A. Emens
DOI: 10.1186/s40425-018-0360-8
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
By Jie Lana, Haiquan Lub, Debangshu Samantab, Shaima Salmanb, You Lua, and Gregg L. Semenza
DOI: 10.1073/pnas.1809695115
A2B adenosine receptor and cancer
By Zhan-Guo Gao, Kenneth A. Jacobson
DOI:10.20944/preprints201910.0149.v1
Host A2B Adenosine Receptors Promote Carcinoma Growth
By Sergey Ryzhov, Sergey V. Novitskiy, Rinat Zaynagetdinov, Anna E. Goldstein, David P. Carbone, Italo Biaggioni, Mikhail M. Dikov, and Igor Feoktistov
DOI: 10.1593/neo.08478
Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
By Deepak Mittal, Debottam Sinha, Deborah Barkauskas, Arabella Young, Murugan Kalimutho, Kimberley Stannard, Franco Caramia, Benjamin Haibe-Kains, John Stagg, Kum Kum Khanna, Sherene Loi, and Mark J. Smyth
DOI: 10.1158/0008-5472.CAN-16-0544
Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2B receptor signaling
By Eisuke Horigome, Michiru Fujieda1, Tadashi Handa, Ayaka Katayama, Masashi Ito, Ami Ichihara, Daiki Tanaka, Navchaa Gombodorj, Shinji Yoshiyama, Arito Yamane, Keiichi Yamada, Jun Horiguchi, Kazuo Shinozuka, Tetsunari Oyama, Masahiko Nishiyama and Susumu Rokudai
Oncotarget, 2018, Vol. 9, (No. 77), pp: 34554-34566
The adenosine A2B receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway
By Yihong Zhou, Xi Chu, Fei Deng, Liang Tong, Guoxiong Tong, Ye Yi, Jianye Liu, Jin Tang, Yuxin Tang, Yang Xia and Yingbo Dai
Oncotarget, 2017, Vol. 8, (No. 30), pp: 48755-48768
Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells
By De-Fu Ma MD, PhD, Tetsuo Kondo MD, PhD, Tadao Nakazawa MD, PhD, Dong-Feng Niu MD, Kunio Mochizuki MD, PhD, Tomonori Kawasaki MD, PhD, Tetsu Yamane MD, Ryohei Katoh MD, PhD
DOI: 10.1016/j.humpath.2010.04.008
Adenosine A2B receptor: novel anti-cancer therapeutic implications
By Silvia Paola Corona, Navid Sobhani, Daniele Generali
DOI: 10.20517/2394-4722.2017.50
Adenosine A2B receptor promotes progression of human oral cancer
By Hiroki Kasama, Yosuke Sakamoto, Atsushi Kasamatsu, Atsushi Okamoto, Tomoyoshi Koyama, Yasuyuki Minakawa, Katsunori Ogawara, Hidetaka Yokoe, Masashi Shiiba, Hideki Tanzawa, and Katsuhiro Uzawa
DOI 10.1186/s12885-015-1577-2
Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation
By Elizabeth A. Vecchio, Christina Y. R. Tan, Karen J. Gregory, Arthur Christopoulos, Paul J. White, and Lauren T. May
DOI: 10.1124/jpet.115.230003
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
By Selena Vigano, Dimitrios Alatzoglou, Melita Irving, Christine Ménétrier-Caux, Christophe Caux, Pedro Romero and George Coukos
DOI: 10.3389/fimmu.2019.00925
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells
By Beatris Mastelic-Gavillet, Blanca Navarro Rodrigo, Laure Décombaz, Haiping Wang, Giuseppe Ercolano, Rita Ahmed, Leyder Elena Lozano, Angela Ianaro, Laurent Derré, Massimo Valerio, Thomas Tawadros, Patrice Jichlinski, Tu Nguyen-Ngoc, Daniel E. Speiser, Grégory Verdeil, Nicolas Gestermann, Olivier Dormond, Lana Kandalaft, George Coukos, Camilla Jandus, Christine Ménétrier-Caux, Christophe Caux, Ping-Chih Ho, Pedro Romero, Alexandre Harari and Selena Vigano
DOI: 10.1186/s40425-019-0719-5
OPTIMISM FOR A2A
By Stephen Hansen, Associate editor
BIOCENTURY TOC
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
By Kevin Sek, Christina Mølck, Gregory D. Stewart, Lev Kats, Phillip K. Darcy and Paul A. Beavis
DOI: 0.3390/ijms19123837
Targeting immunosuppressive adenosine in cancer
By Dipti Vijayan, Arabella Young, Michele W. L. Teng and Mark J. Smyth
DOI: 10.1038/nrc.2017.86